Latest Breaking News On - Lieping chen - Page 1 : comparemela.com

Study uncovers at least one cause of roadblocks to cancer immunotherapy

Study uncovers at least one cause of roadblocks to cancer immunotherapy
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Lieping chenTianxiang zhangYale school of medicineUnited technologies corporation professor in cancer researchYale cancer centerScience immunologyUnited technologies corporation professorCancer researchYale school

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A Wakelee, MD, FASCO

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A Wakelee, MD, FASCO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Stanford universityUnited statesJohns hopkins universitySan diegoYang liuKunliang guanLieping chenMichael caligiuriCatherined macarthurAlexandra foliaslifesci advisorsmediaJeffreys weberHeathera wakeleeNational academy of medicineAmerican association for cancer researchCity of hope medical centerYale university

NextCure Inc (NXTC) Reports Phase 2 Study of NC318 in Combination with Pembrolizumab Shows Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

NextCure Inc (NXTC) Reports Phase 2 Study of NC318 in Combination with Pembrolizumab Shows Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Timothy mayerRoy herbstLieping chenDean for translational researchChen at yale universityExchange commissionUnited technologies corporation professor in cancer researchYale universityYale cancer centerYale school of medicineNextcure incSpecialized program of research excellenceMedicine medical oncology at yale universitySolomon langermannYale cancerSpecialized program

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore BELTSVILLE, Md., Sept. 12, 2023 NextCure,.

Timothy mayerLieping chenRoy herbstYale cancer centerYale school of medicineNextcure incMedicine medical oncology at yale universitySpecialized program of research excellenceDean for translational researchExchange commissionChen at yale universityUnited technologies corporation professor in cancer researchYale universityLung cancerInternational associationSolomon langermann

Normunity appoints industry leader Debanjan Ray to Board of Directors

BOSTON & WEST HAVEN, Conn. (BUSINESS WIRE) Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Debanjan Ray, MBA, to its board of directors. Mr. Ray currently serves as President and Chief Executive Officer of Synthekine, and he has serv.

United statesMassachusetts institute of technologyRachel humphreyDebanjan rayNormunity incUniversity of pennsylvaniaMckinsey companyPortola pharmaceuticalsBristol myers squibbWharton schoolBusiness development at itero biopharmaceuticalsLieping chen at yale school of medicineChief executive officerChief financial officerCytomx therapeuticsBusiness development